Nature Communications (Oct 2017)
Cis P-tau is induced in clinical and preclinical brain injury and contributes to post-injury sequelae
- Onder Albayram,
- Asami Kondo,
- Rebekah Mannix,
- Colin Smith,
- Cheng-Yu Tsai,
- Chenyu Li,
- Megan K. Herbert,
- Jianhua Qiu,
- Michael Monuteaux,
- Jane Driver,
- Sandra Yan,
- William Gormley,
- Ava M. Puccio,
- David O. Okonkwo,
- Brandon Lucke-Wold,
- Julian Bailes,
- William Meehan,
- Mark Zeidel,
- Kun Ping Lu,
- Xiao Zhen Zhou
Affiliations
- Onder Albayram
- Division of Translational Therapeutics, Department of Medicine, Beth Israel Deaconess Medical Center, Harvard Medical School
- Asami Kondo
- Division of Translational Therapeutics, Department of Medicine, Beth Israel Deaconess Medical Center, Harvard Medical School
- Rebekah Mannix
- Division of Emergency Medicine, Children’s Hospital Boston, Harvard Medical School
- Colin Smith
- Department of Neuropathology, University of Edinburgh
- Cheng-Yu Tsai
- Division of Translational Therapeutics, Department of Medicine, Beth Israel Deaconess Medical Center, Harvard Medical School
- Chenyu Li
- Division of Translational Therapeutics, Department of Medicine, Beth Israel Deaconess Medical Center, Harvard Medical School
- Megan K. Herbert
- Division of Translational Therapeutics, Department of Medicine, Beth Israel Deaconess Medical Center, Harvard Medical School
- Jianhua Qiu
- Division of Emergency Medicine, Children’s Hospital Boston, Harvard Medical School
- Michael Monuteaux
- Division of Emergency Medicine, Children’s Hospital Boston, Harvard Medical School
- Jane Driver
- Division of Translational Therapeutics, Department of Medicine, Beth Israel Deaconess Medical Center, Harvard Medical School
- Sandra Yan
- Department of Neurosurgery, Brigham and Women’s Hospital, Harvard Medical School
- William Gormley
- Department of Neurosurgery, Brigham and Women’s Hospital, Harvard Medical School
- Ava M. Puccio
- Department of Neurosurgery, University of Pittsburgh Medical Center
- David O. Okonkwo
- Department of Neurosurgery, University of Pittsburgh Medical Center
- Brandon Lucke-Wold
- Department of Neurosurgery, West Virginia University
- Julian Bailes
- Department of Neurosurgery, NorthShore University Health System, University of Chicago, Pritzker School of Medicine
- William Meehan
- Micheli Center for Sports Injury Prevention, Division of Sports Medicine, Children’s Hospital Boston, Harvard Medical School
- Mark Zeidel
- Department of Medicine, Beth Israel Deaconess Medical Center, Harvard Medical School
- Kun Ping Lu
- Division of Translational Therapeutics, Department of Medicine, Beth Israel Deaconess Medical Center, Harvard Medical School
- Xiao Zhen Zhou
- Division of Translational Therapeutics, Department of Medicine, Beth Israel Deaconess Medical Center, Harvard Medical School
- DOI
- https://doi.org/10.1038/s41467-017-01068-4
- Journal volume & issue
-
Vol. 8,
no. 1
pp. 1 – 17
Abstract
Induction of the cis form of phosphorylated tau (cis P-tau) has previously been shown to occur in animal models of traumatic brain injury (TBI), and blocking this form of tau using antibody was beneficial in a rodent model of severe TBI. Here the authors show that cis P-tau induction is a feature of several different forms of TBI in humans, and that administration of cis P-tau targeting antibody to rodents reduces or delays pathological features of TBI.
